journal
MENU ▼
Read by QxMD icon Read
search

Seminars in Perinatology

journal
https://www.readbyqxmd.com/read/30376986/nanotherapies-for-micropreemies-stem-cells-and-the-secretome-in-bronchopulmonary-dysplasia
#1
REVIEW
Flore Lesage, Bernard Thébaud
Improved survival of extreme preterm infants has made the task of protecting the ever more immature lung from injury more challenging. As a consequence, the incidence of bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity, has remained unchanged. The multifactorial disease pathogenesis of BPD - including amongst others inflammation, oxidative stress and excessive lung stretch - adds further complexity to finding effective therapies that would prevent lung injury and promote lung growth...
October 6, 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30389227/recent-advances-in-antenatal-factors-predisposing-to-bronchopulmonary-dysplasia
#2
REVIEW
Elizabeth Taglauer, Steven H Abman, Roberta L Keller
Bronchopulmonary dysplasia (BPD) remains a major cause of late morbidities and death after preterm birth. BPD is characterized by an arrest of vascular and alveolar growth and high risk for pulmonary hypertension; yet mechanisms contributing to its pathogenesis and early strategies to prevent BPD are poorly understood. Strong epidemiologic studies have shown that the "new BPD" reflects the long-lasting impact of antenatal factors on lung development, partly due to placental dysfunction, as reflected in recent data from animal models...
October 5, 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30420295/introduction
#3
EDITORIAL
Katherine L Kraschel, Natalie Kofler
No abstract text is available yet for this article.
October 4, 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30384985/an-update-on-the-diagnosis-and-management-of-bronchopulmonary-dysplasia-bpd-associated-pulmonary-hypertension
#4
REVIEW
Sara K Berkelhamer, Karen K Mestan, Robin Steinhorn
The past decade of neonatal care has been highlighted by increased survival rates in smaller and more premature infants. Despite reduction in mortality associated with extreme prematurity, long term pulmonary morbidities remain a concern, with growing recognition of the clinical burden attributable to infants with bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension (PH). Recent publications shed light on the critical contributions of maternal placental pathology and compromised intrauterine growth to fetal pulmonary vascular development...
October 4, 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30420296/treatment-of-heritable-diseases-using-crispr-hopes-fears-and-reality
#5
REVIEW
Natalie Kofler, Katherine L Kraschel
CRISPR gene editing is poised to transform the therapeutic landscape for diseases of genetic origin. The ease and agility by which CRISPR can make specific changes to DNA holds great promise not only for the treatment of heritable diseases, but also their prevention through germline editing. CRISPR-based therapeutic strategies are currently under development for numerous monogenic diseases. These strategies range from proof of concept studies demonstrating pre-fertilization gamete editing to recently initiated clinical trials for postnatal ex vivo therapies...
October 2, 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30415764/crispr-diagnostics-underappreciated-uses-in-perinatology
#6
REVIEW
Adam Pan, Katherine L Kraschel
CRISPR-based therapeutics have the potential to revolutionize the treatment of hereditary diseases, but current efforts to translate research to the bedside face significant technical, regulatory, and ethical hurdles. In this article, we discuss an underappreciated application of CRISPR: diagnostic testing, and argue that: (1) CRISPR diagnostics are poised to disrupt diagnostic practices including perinatal screening and (2) since CRISPR diagnostics pose minimal technical, regulatory and ethical hurdles (unlike CRISPR therapeutic uses) they are likely to be clinically relevant before CRISPR-based therapies, and thus warrant medical community's attention...
October 2, 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30401478/an-update-on-pulmonary-and-neurodevelopmental-outcomes-of-bronchopulmonary-dysplasia
#7
REVIEW
Jeanie L Y Cheong, Lex W Doyle
Bronchopulmonary dysplasia (BPD) is a common complication of extreme prematurity, and its rate is not improving, despite advances in perinatal intensive care. Children with BPD diagnosed in the neonatal period have higher risks for hospitalizations for respiratory problems over the first few years of life, and they have more asthma in later childhood. Neonates diagnosed with BPD have substantial airway obstruction on lung function testing in later childhood and early adulthood, and many are destined to develop adult chronic obstructive pulmonary disease...
October 2, 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30389228/compassionate-use-of-gene-therapies-in-pediatrics-an-ethical-analysis
#8
REVIEW
Carolyn P Neuhaus, Rachel L Zacharias
In this commentary, we raise concerns about the compassionate use of CRISPR-mediated gene therapies in pediatric and perinatal patients. There is already a precedent for obtaining gene therapies for pediatric patients through compassionate use programs, and the recent passage of a federal Right to Try law may contribute to an increase in the number of patients who seek access to investigational products outside of a clinical trial. Clinicians, nurses, drug companies, and parents need support as they grapple with whether compassionate use of CRISPR-mediated gene therapies is the right thing to pursue for a child...
October 2, 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30384986/recent-advances-in-the-pathogenesis-of-bpd
#9
REVIEW
Rory E Morty
Bronchopulmonary dysplasia (BPD) continues to be one of the most common complications of preterm birth and is characterized histopathologically by impaired lung alveolarization. Extremely preterm born infants remain at high risk for the development of BPD, highlighting a pressing need for continued efforts to understand the pathomechanisms at play in affected infants. This brief review summarizes recent progress in our understanding of the how the development of the newborn lung is stunted, highlighting recent reports on roles for growth factor signaling, oxidative stress, inflammation, the extracellular matrix and proteolysis, non-coding RNA, and fibroblast and epithelial cell plasticity...
October 2, 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30376985/crispr-in-personalized-medicine-industry-perspectives-in-gene-editing
#10
REVIEW
Andrew Hong
While research in gene editing technology has been active since the 1990s, recent advances in CRISPR ease of use have sparked significant enthusiasm in the biomedical community. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene editing has the potential to shape the therapeutic landscape of genetically-defined diseases, with key players such as CRISPR Therapeutics, Intellia, and Editas leading the way in β-thalassemia and sickle cell disease. In coming years, clinical development of CRISPR technology promises to change how we think about monogenic and polygenic diseases, though data is still in its infancy...
October 2, 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30343941/surfactant-steroids-and-non-invasive-ventilation-in-the-prevention-of-bpd
#11
REVIEW
Vikramaditya Dumpa, Vineet Bhandari
Bronchopulmonary dysplasia (BPD) is a complex disorder with multiple factors implicated in its etiopathogenesis. Despite the scientific advances in the field of neonatology, the incidence of BPD has remained somewhat constant due to increased survival of extremely premature infants. Surfactant deficiency in the immature lung, exposure to invasive mechanical ventilation leading to volutrauma, barotrauma and lung inflammation are some of the critical contributing factors to the pathogenesis of BPD. Hence, strategies to prevent BPD in the postnatal period revolve around mitigation of this injury and inflammation...
October 2, 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30241950/industry-perspectives-on-prenatal-genetic-testing
#12
REVIEW
Amy Swanson, James D Goldberg
Until recent years, prenatal genetic tests have been almost exclusively developed and implemented by academic physicians and laboratories. In the last several years, industry has led the development of novel prenatal genetic tests, funded clinical trials and implemented these tests into clinical practice. That these efforts have been driven by industry has raised questions about diagnostics development regulations, consistency in reporting of results, and management of potential conflicts of interest. In this article, these topics are addressed from an industry perspective...
August 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30241949/prenatal-genetic-carrier-screening-in-the-genomic-age
#13
REVIEW
Anthony R Gregg, Janice G Edwards
The Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists (ACOG), and American College of Medical Genetics and Genomics (ACMG) held a workshop entitled "Prenatal Genetic Testing" on January 25, 2017 to address several questions arising from the increasing implementation of preconception and prenatal expanded carrier screening (ECS). ECS allows for identification of a greater number of genetic sequencing changes (not all of which cause disease) and simultaneous testing for an increased number of genetic conditions without limitation to specific ethnic groups...
August 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30209012/optimizing-use-of-existing-prenatal-genetic-tests-screening-and-diagnostic-testing-for-aneuploidy
#14
REVIEW
Katie Stoll, Mary E Norton
Screening and diagnostic testing for detection of fetal aneuploidy has been an integral part of prenatal care for over three decades. The recent introduction of new technologies, such as cell free DNA (cfDNA) screening and preimplantation genetic screening, has created increased complexity for obstetrical care providers. Inconsistencies among the professional society recommendations have caused confusion and disparities in practice. As we work to responsibly incorporate new technologies, clear guidelines with consensus among relevant professional societies are needed...
August 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30206017/laboratory-considerations-for-prenatal-genetic-testing
#15
REVIEW
Karen Wou, Wendy K Chung, Ronald J Wapner
New genetic tests have rapidly entered clinical care with little consistency in laboratory testing and reporting. Non-invasive prenatal screening using cell free DNA (cfDNA) may either screen for common aneuploidies alone or include chromosomal microdeletions. All cfDNA screening tests have false positives and false negatives, and accordingly laboratories should report positive and negative predictive values. In addition, since fetal fraction plays a significant role in the reliability of results, this should also be reported with all test results...
August 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30195989/what-are-the-goals-of-prenatal-genetic-testing
#16
REVIEW
Stephanie Dukhovny, Mary E Norton
The landscape of genetic testing and screening has changed tremendously since the initial description of the molecular structure of DNA. Given this, it is critical that providers reflect on the goals of prenatal screening and diagnostic testing, and how these tests impact perinatal outcomes. The participants of this workshop were in agreement that the goal of prenatal genetic testing should be focused on improving outcomes for women and families. While prenatal testing has historically focused on the option for pregnancy termination, increasing numbers of prenatal and perinatal treatments are available...
August 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30195988/preface
#17
REVIEW
Mary E Norton, Ronald J Wapner
No abstract text is available yet for this article.
August 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30173949/how-should-costs-and-cost-effectiveness-be-considered-in-prenatal-genetic-testing
#18
REVIEW
Teresa N Sparks, Aaron B Caughey
In January 2017, a group of experts in prenatal genetics attended a workshop at the Society of Maternal-Fetal Medicine meeting to review the evidence behind the costs and cost-effectiveness of prenatal genetic testing. Over the past decade, prenatal genetic testing options have dramatically expanded to include additional options with cell-free DNA (cfDNA) screening, as well as increased diagnostic abilities through chromosomal microarray analysis (CMA), gene panels, whole exome sequencing, and other tests. With these expanding technologies, it is important to consider the options available as well as the cost effectiveness of their use...
August 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30115457/introducing-new-and-emerging-genetic-tests-into-prenatal-care
#19
REVIEW
Neeta L Vora, Ronald J Wapner
Given the rapid advances in genomics, translating new genomic tests effectively into prenatal clinical practice remains challenging. We discuss emerging genetic tests, considerations for their use, how tests should ideally be validated prior to use in clinical practice, and the role of the Federal Drug Administration, Clinical Laboratory Improvement Amendments (CLIA) laboratories, commercial laboratories, insurers, and professional societies such as the American College of Obstetricians and Gynecologists (ACOG), and the Society for Maternal-Fetal Medicine (SMFM) in the introduction of new prenatal genetic tests...
August 2018: Seminars in Perinatology
https://www.readbyqxmd.com/read/30107889/what-are-the-required-components-of-pre-and-post-test-counseling
#20
REVIEW
Britton D Rink, Jeffrey A Kuller
Prenatal care providers are faced with a myriad of decisions about how to offer genetic screening and testing in ways that are appropriate to their patient population and their workflow. Among the critical issues brought to the forefront of rapidly advancing genetic and genomic technologies is the importance of pre- and post-test counseling. This document is a synthesis of proceedings of a workshop sponsored by the American College of Obstetricians and Gynecologists, the American College of Medical Genetics and Genomics, and the Society for Maternal-Fetal Medicine, on January 24-25, 2017, during which invited experts discussed required components of pre- and post-test counseling and associated concerns in the provision of prenatal care...
August 2018: Seminars in Perinatology
journal
journal
20240
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"